



CathRx Ltd
ABN 23 089 310 421
5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

ASX Announcement

CathRx Submits CE Mark application for its first therapeutic catheter designed to treat cardiac arrhythmias



SYDNEY Australia 4 January 2010

Cardiac catheter manufacturer CathRx Limited (ASX:CXD) today announced that it had submitted an application for CE Marking of its irrigated ablation catheter coupled with the Company's variable deflectable stylet. The irrigated ablation catheter will be the first catheter in the Company's therapeutic catheter range designed for use in the treatment of cardiac arrhythmias.

CathRx Chief Executive Officer, Neil Anderson said, "When this irrigated ablation catheter receives CE Mark approval, we'll have a complete modular catheter offering for the diagnosis and treatment of atrial flutter and atrial fibrillation. This will allow CathRx to provide both diagnostic and therapeutic catheters to the European market."

End

About CathRx

CathRx is a medical device company which manufactures and markets advanced cardiac catheter solutions for the treatment of people suffering from electrical problems of the heart known as cardiac arrhythmias. CathRx's proprietary diagnostic and therapeutic catheters are designed to give physicians the tools to successfully treat patients with speed, safety and precision. CathRx's diagnostic products are now being sold in Europe.

About cardiac arrhythmias

Cardiac arrhythmia describes a group of increasingly common conditions where there is abnormal electrical activity in the heart. The beating of a normal heart is controlled by electrical impulses. When these impulses are uncoordinated the heart fails to function properly. This can result in complications ranging from fatigue to stroke and even death. More than 10 million people worldwide suffer from abnormal heart rhythms. Atrial fibrillation is the most common form of arrhythmia and affects over 5 million people worldwide. Current drug therapies often fail to control the problem and can have side effects. Physicians worldwide are increasingly using cardiac catheters to diagnose and successfully treat arrhythmias.



CathRx Ltd
ABN 23 089 310 421
5 Parkview Drive
Homebush Bay NSW 2127
Australia
Telephone +61 (0)2 9397 5700
Facsimile +61 (0)2 9397 5701
www.cathrx.com

Would you like to receive CathRx ASX releases via email?

Go to www.cathrx.com and become a subscriber to our investor communications.

For further information:

Neil Anderson
CathRx Chief Executive Officer
Telephone: +61 2 9397 5700

Amanda Wong
CathRx Chief Financial Officer
Telephone: +61 2 9397 5700

